BioTime’s Subsidiary LifeMap Sciences Announces Release of LifeMap Discovery™ Version 1.5 with GeneAnalytics™, a Powerful Gene Expression Analysis Tool
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 17, 2014--
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the release of LifeMap Discovery™ version 1.5 (discovery.lifemapsc.com).
LifeMap Discovery™ is a state-of-the-art roadmap of embryonic
development and stem cell biology. The product integrates embryonic
development and stem cell biology, molecular, cellular, anatomical, and
disease-related information, and provides data-mining capabilities and
bioinformatics applications. As such, it is a unique and powerful tool
for research and discovery in multiple disciplines, including stem cell
biology, developmental biology, disease mechanisms and etiology.
LifeMap Discovery™ is a key component in LifeMap’s integrated
database suite, a discovery platform for biomedical and stem cell
research, which also includes GeneCards®, the
leading human gene database (www.genecards.org),
and MalaCards, the human disease database (www.malacards.org).
LifeMap Sciences holds the exclusive worldwide license to market GeneCards®
and MalaCards from Yeda Research and Development Company Ltd.,
the commercial arm of the Weizmann Institute of Science.
Version 1.5 of LifeMap Discovery™ includes the following new
– this powerful gene expression analysis tool integrates and
clusters data extracted from multiple and variable resources, in order
to identify tissue-specific gene expression patterns. It supports
analysis of multiple genes and applies a novel algorithm to match gene
sets to tissues, anatomical compartments and cells in vivo and in
vitro within LifeMap Discovery™. As such, it is the most
comprehensive analysis tool for modeling gene expression data in the
embryo and the adult body.
cards for cell therapy approaches - information about diseases
that can potentially benefit from cell-based treatments, including
degenerative diseases, intractable diseases, disorders and injuries,
which are characterized by cell death or aberrant cellular function.
Improved display of signaling– LifeMap Discovery™ details
~2,000 development-associated signals and their cascades. In this
version we have significantly improved our modeling and display of
signals affecting cell development, thus enhancing the development of
novel differentiation protocols.
Updated development paths for:
cell development was updated with new gene expression and signaling
mesenchymal stem cells (MSCs) were mapped in-vivo with their gene
expression profile and developmental origin
77 new differentiation protocols and 126 new in vitro cells were
mapped, particularly updated the following cell types:
45 new high
throughput experiments and large scale datasets including the
integration of the GNF BioGPS dataset, and a proprietary cultured
cells collection dataset that includes differential expression data
for 131 human primary cells and stem cells.
96 new cell therapy applications, in an ongoing effort to cover the cell
therapy applications developed by industry and nonprofit
“Version 1.5 is a significant step forward in our coverage of stem cell
and developmental data,” said Ronit Shtrichman, Ph.D., MBA, Vice
President of Biology at LifeMap Sciences. “The addition of GeneAnalytics
as a platform for identifying gene expression in cells and tissues is
going to be a game-changer for our customers. This novel tool, which
leverages both our manually annotated data, as well as high throughput
data, will enable stem cells researchers to identify their cells and
tissues during differentiation processes and accelerate their research.”
“We’re very happy to see how well received our platform has been with
stem cell researchers in both academia and industry,” stated Yaron
Guan-Golan, Head of Marketing at LifeMap Sciences. “Our recent
presentation at World Stem Cell Summit, San Diego, has opened up many
doors for collaboration in both commercial and academic spaces, and we
will be pursuing them aggressively in the coming months.”
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com)
core technology and business is based on its Integrated Biomedical
Knowledgebase and discovery platform for biomedical research, which
currently includes GeneCards®:
the leading human gene database; LifeMap
Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards,
the human disease database. LifeMap’s products are used in many
institutions including academia, research hospitals, patent offices, and
leading biotechnology and pharmaceutical companies. LifeMap is also
engaged in therapeutics discovery, utilizing LifeMap’s proprietary
platform to aid in the development of products for the treatment of
degenerative diseases, including utilizing BioTime’s proprietary, PureStem™
human progenitor cell lines. In addition to its currently marketed
products, LifeMap is pursuing several new internet and informatics
products with substantial rapid revenue growth potential, leveraging its
existing products and their large user base.
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary PureStem™
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood plasma volume
expander for use in surgery, emergency trauma treatment and other
applications. Hextend® is manufactured and distributed
in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang
Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
• Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired
the stem cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment for
the development of new therapeutic products for regenerative medicine.
• OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
• Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an
Israel-based biotechnology company focused on developing stem cell-based
therapies for retinal and neurological disorders, including the
development of retinal pigment epithelial cells for the treatment of
macular degeneration, and treatments for multiple sclerosis.
• LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and
distributes GeneCards®, the leading human gene
database, as part of an integrated database suite that also includes the LifeMap
Discovery™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database.
• ES Cell International Pte Ltd., a Singapore private limited company,
developed clinical and research grade hES cell lines and plans to market
those cell lines and other BioTime research products in over-seas
markets as part of BioTime’s ESI BIO Division.
• BioTime Asia, Limited, a Hong Kong company, may offer and sell
products for research use for BioTime’s ESI BIO Division.
• OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
• ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of cardiovascular and related ischemic disorders, as well as products
for research using cell reprogramming technology.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
Source: BioTime, Inc.
Lesley Stolz, 510-521-3390 ext. 367
Vice President Corporate Development
Segall, 510-521-3390 ext. 301
Kenneth Elsner, 781-826-7719
CFO and General